RU2013149168A - Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования - Google Patents

Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования Download PDF

Info

Publication number
RU2013149168A
RU2013149168A RU2013149168/04A RU2013149168A RU2013149168A RU 2013149168 A RU2013149168 A RU 2013149168A RU 2013149168/04 A RU2013149168/04 A RU 2013149168/04A RU 2013149168 A RU2013149168 A RU 2013149168A RU 2013149168 A RU2013149168 A RU 2013149168A
Authority
RU
Russia
Prior art keywords
subject
compound according
nephrotoxicity
induced
treatment
Prior art date
Application number
RU2013149168/04A
Other languages
English (en)
Inventor
Джон Дэвид Имиг
Уилльям Б. Кэмпбелл
Джон Рассел Фок
Original Assignee
Дзе Медикал Колледж Оф Висконсин
Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2013149168(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Медикал Колледж Оф Висконсин, Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем filed Critical Дзе Медикал Колледж Оф Висконсин
Publication of RU2013149168A publication Critical patent/RU2013149168A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • C07C323/44X or Y being nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/071,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C07D277/593Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/04Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

1. Соединение, выбранное из группы, состоящей из2. Соединение по п. 1, где структура представляет собой3. Соединение по п. 1, где структура представляет собой4. Соединение, выбранное из группы, состоящей из5. Композиция, включающая соединение по п.1 или 4 и фармацевтически приемлемый носитель.5. Способ снижения гипертензии у субъекта, включающий введение субъекту терапевтически эффективного количества соединения по п.1 или 4, где гипертензия у указанного субъекта снижается.6. Применение соединения по п.1 или 4 для получения лекарственного средства для лечения гипертензии у субъекта.7. Соединение по п.1 или 4 для применения в лечении гипертензии у субъекта.8. Способ снижения нефротоксичности у субъекта, включающий введение субъекту терапевтически эффективного количества соединения по п.1 или 4, где нефротоксичность у указанного субъекта снижается.9. Способ по п. 8, где нефротоксичность является лекарственно-индуцированной.10. Способ по п. 9, где нефротоксичность является цисплатин-индуцированной.11. Применение соединения по п.1 или 4 для получения лекарственного средства для лечения лекарственно-индуцированной нефротоксичности у субъекта.12. Соединение по п.1 или 4 для применения в лечении лекарственно-индуцированной нефротоксичности у субъекта.13. Способ снижения цисплатин-индуцированной нефротоксичности у субъекта, включающий введение субъекту терапевтически эффективного количества соединения по п.1 или 4, где цисплатин-индуцированная нефротоксичность у указанного субъекта снижается.14. Применение соединения по п.1 или 4 для получения лекарственного препарата для лечения цисплатин-индуцированной нефротоксичности у субъе�

Claims (15)

1. Соединение, выбранное из группы, состоящей из
Figure 00000001
2. Соединение по п. 1, где структура представляет собой
Figure 00000002
3. Соединение по п. 1, где структура представляет собой
Figure 00000003
4. Соединение, выбранное из группы, состоящей из
Figure 00000004
5. Композиция, включающая соединение по п.1 или 4 и фармацевтически приемлемый носитель.
5. Способ снижения гипертензии у субъекта, включающий введение субъекту терапевтически эффективного количества соединения по п.1 или 4, где гипертензия у указанного субъекта снижается.
6. Применение соединения по п.1 или 4 для получения лекарственного средства для лечения гипертензии у субъекта.
7. Соединение по п.1 или 4 для применения в лечении гипертензии у субъекта.
8. Способ снижения нефротоксичности у субъекта, включающий введение субъекту терапевтически эффективного количества соединения по п.1 или 4, где нефротоксичность у указанного субъекта снижается.
9. Способ по п. 8, где нефротоксичность является лекарственно-индуцированной.
10. Способ по п. 9, где нефротоксичность является цисплатин-индуцированной.
11. Применение соединения по п.1 или 4 для получения лекарственного средства для лечения лекарственно-индуцированной нефротоксичности у субъекта.
12. Соединение по п.1 или 4 для применения в лечении лекарственно-индуцированной нефротоксичности у субъекта.
13. Способ снижения цисплатин-индуцированной нефротоксичности у субъекта, включающий введение субъекту терапевтически эффективного количества соединения по п.1 или 4, где цисплатин-индуцированная нефротоксичность у указанного субъекта снижается.
14. Применение соединения по п.1 или 4 для получения лекарственного препарата для лечения цисплатин-индуцированной нефротоксичности у субъекта.
15. Соединение по п.1 или 4 для применения в лечении цисплатин-индуцированной нефротоксичности у субъекта.
RU2013149168/04A 2011-04-06 2012-04-04 Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования RU2013149168A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161472410P 2011-04-06 2011-04-06
US61/472,410 2011-04-06
US201261608361P 2012-03-08 2012-03-08
US61/608,361 2012-03-08
PCT/US2012/032090 WO2012138706A1 (en) 2011-04-06 2012-04-04 Epoxyeicosatrienoic acid analogs and methods of making and using the same

Publications (1)

Publication Number Publication Date
RU2013149168A true RU2013149168A (ru) 2015-05-20

Family

ID=46172875

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013149168/04A RU2013149168A (ru) 2011-04-06 2012-04-04 Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования

Country Status (25)

Country Link
US (2) US9127027B2 (ru)
EP (1) EP2694470B1 (ru)
JP (1) JP5991766B2 (ru)
KR (1) KR20140037075A (ru)
CN (1) CN103764621B (ru)
AU (1) AU2012240256C1 (ru)
BR (1) BR112013025740A2 (ru)
CA (1) CA2832422C (ru)
CL (1) CL2013002861A1 (ru)
CO (1) CO6842021A2 (ru)
CR (1) CR20130569A (ru)
EA (1) EA023104B1 (ru)
EC (1) ECSP13013012A (ru)
ES (1) ES2593905T3 (ru)
GE (1) GEP20166444B (ru)
HK (1) HK1197230A1 (ru)
IL (1) IL228708A (ru)
MA (1) MA35100B1 (ru)
MX (1) MX337597B (ru)
NI (1) NI201300102A (ru)
PE (1) PE20141155A1 (ru)
RU (1) RU2013149168A (ru)
SG (1) SG194075A1 (ru)
UA (1) UA111357C2 (ru)
WO (1) WO2012138706A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103764621B (zh) * 2011-04-06 2015-05-27 威斯康星州医药大学股份有限公司(美国) 环氧化二十碳三烯酸类似物、其制备方法及其应用
EP2922817A4 (en) * 2012-11-21 2016-06-22 Univ Sydney OMEGA-3 ANALOGUES
KR102392893B1 (ko) * 2014-01-22 2022-04-29 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 신규한 cyp-아이코사노이드 유도체
EP3313816B1 (en) * 2015-07-22 2023-05-24 OMEICOS Therapeutics GmbH Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease
US11690825B2 (en) 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
BR112018070194A2 (pt) * 2016-04-01 2019-01-29 Max Delbrueck Centrum Fuer Molekulare Medizin composto e composição para uso
US20190117597A1 (en) * 2016-04-01 2019-04-25 Omeicos Therapeutics Gmbh Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation
KR102012554B1 (ko) * 2016-07-13 2019-08-23 주식회사 노브메타파마 사이클로 히스티딘-프롤린을 유효성분으로 포함하는 세포 보호용 조성물
EP3681887B1 (en) * 2017-09-15 2024-09-04 The Medical College of Wisconsin, Inc. Kidney-targeted epoxyeicosatrienoic acid (eet) analogs
WO2021067590A1 (en) * 2019-10-01 2021-04-08 University Of Kentucky Research Foundation Method for treatment of alzheimer's disease
CN111548366B (zh) * 2020-05-27 2023-05-02 广东德美精细化工集团股份有限公司 一种无甲醛棉用阻燃剂、制备方法及应用
JP7166475B1 (ja) 2022-02-14 2022-11-07 悠 澤村 腎毒性軽減用組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4663308A (en) 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US7732470B2 (en) * 2006-10-02 2010-06-08 Medical College Of Georgia Research Institute Compositions and methods for the treatment of renal and cardiovascular disease
US7550617B2 (en) 2006-10-02 2009-06-23 Medical College Of Georgia Research Institute Compositions and methods for the treatment of renal and cardiovascular disease
EP2208720A1 (en) * 2009-01-13 2010-07-21 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Novel eicosanoid derivatives
CN103764621B (zh) * 2011-04-06 2015-05-27 威斯康星州医药大学股份有限公司(美国) 环氧化二十碳三烯酸类似物、其制备方法及其应用

Also Published As

Publication number Publication date
HK1197230A1 (en) 2015-01-09
EA023104B1 (ru) 2016-04-29
CL2013002861A1 (es) 2014-06-13
IL228708A0 (en) 2013-12-31
US9422318B2 (en) 2016-08-23
ES2593905T3 (es) 2016-12-14
CO6842021A2 (es) 2014-01-20
US9127027B2 (en) 2015-09-08
CA2832422A1 (en) 2012-10-11
CN103764621B (zh) 2015-05-27
AU2012240256B2 (en) 2016-12-08
PE20141155A1 (es) 2014-09-21
EP2694470A1 (en) 2014-02-12
JP5991766B2 (ja) 2016-09-14
MX2013011627A (es) 2014-03-27
ECSP13013012A (es) 2014-12-30
AU2012240256C1 (en) 2017-03-09
CR20130569A (es) 2014-04-22
IL228708A (en) 2016-10-31
CN103764621A (zh) 2014-04-30
AU2012240256A1 (en) 2013-11-21
NI201300102A (es) 2014-05-29
KR20140037075A (ko) 2014-03-26
EP2694470B1 (en) 2016-06-01
JP2014517816A (ja) 2014-07-24
MA35100B1 (fr) 2014-05-02
US20150336916A1 (en) 2015-11-26
UA111357C2 (ru) 2016-04-25
NZ617402A (en) 2015-10-30
WO2012138706A1 (en) 2012-10-11
EA201391481A1 (ru) 2014-04-30
MX337597B (es) 2016-03-11
CA2832422C (en) 2020-07-28
US20140113884A1 (en) 2014-04-24
BR112013025740A2 (pt) 2016-12-13
GEP20166444B (en) 2016-03-10
SG194075A1 (en) 2013-11-29

Similar Documents

Publication Publication Date Title
RU2013149168A (ru) Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
JP2013032389A5 (ru)
GT201200158A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
EP4245369A3 (en) Neuroactive steroids, compositions, and uses thereof
IN2014CN00562A (ru)
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
JP2013542247A5 (ru)
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
RU2013121788A (ru) Ингибиторы репликации вич
EA201490650A1 (ru) Фармацевтические композиции
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
EA201171284A1 (ru) Новая технология изготовления напроксена
PH12014500990A1 (en) Methods for treating gout flares
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
EA201391211A1 (ru) Новые соединения в качестве лигандов гистаминовых h-рецепторов
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
EA201490573A1 (ru) Соединение бензотиазолона
RU2012145176A (ru) Композиции против эндопаразитов
EA201490233A1 (ru) Стабильные лекарственные формы артеролана и пиперахина
RU2015141335A (ru) 2β,3α,5α-ТРИГИДРОКСИ-АНДРОСТ-6-ОН, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JP2013502449A5 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160920